Title: HIV and hepatitis B co-infection in Africa
Authors: Lessells RJ, Main J, Cooke GS.
Journal: Lancet Infectious Diseases,8:210-11 (2008)
Journal Impact Factor (I.F.): 16.144
Number of citations (Google Scholar): 8
The Review by Christopher Hoff mann and Chloe Thio1
brings to the fore the issue of HIV and hepatitis B virus
(HBV) co-infection in resource-poor settings. We
support their call for further research in this fi eld.
The management of HIV/HBV co-infection in highincome
settings involves individualised therapy usually
from an expert provider with the support of an array of
diagnostic tests. The primary goal of this treatment is to
reduce the risk of cirrhosis and hepatocellular carcinoma.
However, the public-health approach to antiretroviral
therapy (ART) aims to maximise survival at the
population level.2 ART programmes in Africa and other
resource-poor settings involve standardised treatment
protocols and simplifi ed monitoring to achieve best
possible use of available resources. The treatment of
hepatitis B is already entwined with the roll-out of
ART since lamivudine, a key drug in most fi rst-line HIV
treatment combinations, is also active against HBV.
Citation: Lessells RJ, Main J, Cooke GS. HIV and hepatitis B co-infection in Africa Lancet Infectious Diseases,8:210-11 (2008).